Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
Alkermes to Present at the 41st Annual J.P. Morgan Healthcare Conference
04:00pm, Wednesday, 28'th Dec 2022
DUBLIN , Dec. 28, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 41st Annual J.P.
Analyst Ratings for Alkermes
09:04pm, Tuesday, 06'th Dec 2022 Benzinga
Over the past 3 months, 4 analysts have published their opinion on Alkermes (NASDAQ:ALKS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a compan
Alkermes (ALKS) Up 4.4% Since Last Earnings Report: Can It Continue?
04:31pm, Friday, 02'nd Dec 2022 Zacks Investment Research
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alkermes (ALKS) Up 4.4% Since Last Earnings Report: Can It Continue?
12:48pm, Friday, 02'nd Dec 2022
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
How Alkermes (ALKS) Stock Stands Out in a Strong Industry
01:40pm, Wednesday, 23'rd Nov 2022 Zacks Investment Research
Alkermes (ALKS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
How Alkermes (ALKS) Stock Stands Out in a Strong Industry
09:47am, Wednesday, 23'rd Nov 2022
Alkermes (ALKS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022
02:13pm, Thursday, 03'rd Nov 2022 Benzinga
Upgrades
According to Baird, the prior rating for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) was changed from Neutral to Outperform. Ultragenyx Pharmaceutical earned $2.43 in the third quarter, comp
Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss
03:43pm, Wednesday, 02'nd Nov 2022 Zacks Investment Research
Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.
Alkermes plc (ALKS) Q3 2022 Earnings Call Transcript
01:41pm, Wednesday, 02'nd Nov 2022
Alkermes plc (NASDAQ:ALKS ) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Sandra Coombs - SVP, IR & Corporate Affairs Richard Pops - CEO Iain Brown - CFO Todd Nicho
Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss
12:48pm, Wednesday, 02'nd Nov 2022
Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.
Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
02:00pm, Friday, 28'th Oct 2022 Zacks Investment Research
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes, Allakos See Activist Action
06:35pm, Friday, 14'th Oct 2022
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2022
02:37pm, Friday, 14'th Oct 2022 Benzinga
Upgrades
For Enviva Inc (NYSE:EVA), Citigroup upgraded the previous rating of Neutral to Buy. For the second quarter, Enviva had an EPS of $0.26, compared to year-ago quarter EPS of $0.24. The curren
Domino's Pizza To Rally 20%? Here Are 5 Other Price Target Changes For Friday
11:24am, Friday, 14'th Oct 2022 Benzinga
Wedbush raised Domino's Pizza, Inc. (NYSE: DPZ) price target from $370 to $400. Wedbush analyst Nick Setyan maintained an Outperform rating on the stock. Domino's shares rose 10.4% to close at $333.2
Alkermes: Nothing Stands Out As Interesting
03:02pm, Monday, 26'th Sep 2022
Alkermes plc has a slew of revenue earning products in CNS. It is refocusing itself on oncology assets.
